 The study found that AV-101, dry powder inhaled formulation of imatinab was safe and well tolerated when administered to healthy adults. It also showed that AV-101 significantly reduced the systemic exposure of imatinab compared to oral imatinab, suggesting that it may have improved tolerability without compromising efficacy. This article was authored by Hunter Gillies, Ralph Niven, Benjamin Teedake and others.